{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:06:06Z","timestamp":1769825166592,"version":"3.49.0"},"reference-count":31,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: To evaluate the one-year outcomes of intravitreal ranibizumab biosimilar (RBZ-BS) injections for myopic choroidal neovascularization (mCNV) in Japanese patients. Methods: Twenty-one patients (mean age 69.0 years; 4 males, 17 females) with high myopia and mCNV were retrospectively reviewed. Twelve were treatment-na\u00efve, and nine had previous anti-VEGF treatments. Efficacy measures included best-corrected visual acuity (BCVA) and central macular thickness (CMT). Results: The treatment-na\u00efve group showed significant BCVA improvement from 0.55 \u00b1 0.34 at baseline to 0.24 \u00b1 0.28 at 12 months. The previously treated group had no significant BCVA changes. CMT significantly decreased in both groups: from 295.3 \u00b1 105.2 \u00b5m to 207.3 \u00b1 63.0 \u00b5m in the treatment-na\u00efve group, and from 196.1 \u00b1 62.0 \u00b5m to 147.2 \u00b1 50.1 \u00b5m in the previously treated group. Dry macula rates were high: 83% at 3 months and 83% at 12 months in the treatment-na\u00efve group, and 67% at 3 months and 89% at 12 months in the previously treated group. No adverse events were reported. Conclusions: These findings indicate that RBZ-BS is an effective and safe treatment for mCNV, particularly in treatment-na\u00efve patients. The use of RBZ-BS offers a cost-effective alternative to original ranibizumab, reducing financial burdens while maintaining high therapeutic efficacy. Further studies with larger sample sizes and longer follow-up periods are needed to confirm these results and evaluate long-term outcomes and cost-effectiveness.<\/jats:p>","DOI":"10.3390\/jcm13164641","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T07:01:25Z","timestamp":1723100485000},"page":"4641","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["One-Year Outcome of Intravitreal Injection of Ranibizumab Biosimilar for Myopic Choroidal Neovascularization in Japanese Patients"],"prefix":"10.3390","volume":"13","author":[{"given":"Mami","family":"Tomita","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6666-8706","authenticated-orcid":false,"given":"Manabu","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akika","family":"Kyo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiko","family":"Misawa","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen","family":"Kinari","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeya","family":"Kohno","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0632-997X","authenticated-orcid":false,"given":"Shigeru","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.12.001","article-title":"Updates of pathologic myopia","volume":"52","author":"Lai","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/01.icu.0000120709.35941.e9","article-title":"Myopic choroidal neovascularization: Natural course and treatment","volume":"15","author":"Yoshida","year":"2004","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006982-199212020-00009","article-title":"Pathologic findings in pathologic myopia","volume":"12","author":"Grossniklaus","year":"1992","journal-title":"Retina"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.preteyeres.2012.04.001","article-title":"Choroidal neovascularization in pathological myopia","volume":"31","author":"Neelam","year":"2012","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: An evidence-based systematic review","volume":"157","author":"Wong","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7532","DOI":"10.1167\/iovs.13-12795","article-title":"The economic cost of myopia in adults aged over 40 years in Singapore","volume":"54","author":"Zheng","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/mvre.2002.2407","article-title":"Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes","volume":"64","author":"Otani","year":"2002","journal-title":"Microvasc. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1097\/IAE.0b013e31818358b2","article-title":"Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia","volume":"28","author":"Chan","year":"2008","journal-title":"Retina"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1755-3768.2009.01843.x","article-title":"EXTEND-I: Safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration","volume":"88","author":"Tano","year":"2010","journal-title":"Acta Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ophtha.2010.08.016","article-title":"Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study","volume":"117","author":"Nguyen","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: A randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.2147\/OPTH.S307746","article-title":"Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration","volume":"15","author":"Apsangikar","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamaophthalmol.2020.5053","article-title":"Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial","volume":"139","author":"Woo","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ophtha.2021.04.031","article-title":"Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration","volume":"129","author":"Holz","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/IAE.0000000000003626","article-title":"Anti-vascular endothelial growth factor biosimilars in ophthalmology","volume":"42","author":"Kaiser","year":"2022","journal-title":"Retina"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/bjophthalmol-2021-319637","article-title":"Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes","volume":"107","author":"Bressler","year":"2023","journal-title":"Br. J. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41433-022-02246-5","article-title":"Approved biosimilar ranibizumab-a global update","volume":"37","author":"Sharma","year":"2023","journal-title":"Eye"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s40123-023-00715-y","article-title":"Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan","volume":"12","author":"Yanagi","year":"2023","journal-title":"Ophthalmol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40123-022-00488-w","article-title":"An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review","volume":"11","author":"Hariprasad","year":"2022","journal-title":"Ophthalmol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2147\/DDDT.S457303","article-title":"Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution?","volume":"18","author":"Chatzimichail","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/postmj\/qgae016","article-title":"Advancements in the treatment of age-related macular degeneration: A comprehensive review","volume":"100","author":"Papaioannou","year":"2024","journal-title":"Postgrad. Med. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10384-014-0363-z","article-title":"Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab","volume":"59","author":"Cohen","year":"2015","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5301\/EJO.2011.7750","article-title":"Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization","volume":"22","author":"Matsuo","year":"2012","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8639243","DOI":"10.1155\/2019\/8639243","article-title":"Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results-A Retrospective, Comparative Study","volume":"2019","author":"Erden","year":"2019","journal-title":"J. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ceo.13424","article-title":"Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-month results from a randomized controlled study","volume":"47","author":"Li","year":"2019","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00417-018-04205-x","article-title":"Vascular remodeling of choroidal neovascularization in older myopic patients treated with ranibizumab","volume":"257","author":"Cohen","year":"2019","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ajo.2015.07.004","article-title":"Spectral-Domain Optical Coherence Tomography of Subretinal Hyperreflective Exudation in Myopic Choroidal Neovascularization","volume":"160","author":"Caillaux","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Castellino, N., Battaglia Parodi, M., Russo, A., Toro, M.D., Fallico, M., Bonfiglio, V., Maugeri, A.D., Avitabile, T., and Longo, A. (2022). Morphological parameters of myopic choroidal neovascularization as predictive factors of anti-VEGF treatment response. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-14287-7"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2147\/OPTH.S461846","article-title":"Factors Involved in Anti-VEGF Treatment Decisions for Neovascular Age-Related Macular Degeneration: Insights from Real-World Clinical Practice","volume":"18","author":"Yiu","year":"2024","journal-title":"Clin. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2147\/OPTH.S180393","article-title":"Biosimilars in ophthalmology: \u201cIs there a big change on the horizon?\u201d","volume":"12","author":"Sharma","year":"2018","journal-title":"Clin. Ophthalmol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/16\/4641\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:31:56Z","timestamp":1760110316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/16\/4641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":31,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["jcm13164641"],"URL":"https:\/\/doi.org\/10.3390\/jcm13164641","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]}}}